111In-pentetreotide SPECT/CT in pulmonary carcinoid

Agostino Chiaravalloti, Angela Spanu, Roberta Danieli, Francesca Dore, Bastiana Piras, Antonio Falchi, Mario Tavolozza, Giuseppe Madeddu, Orazio Schillaci

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: We evaluated somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). Patients and Methods: We enrolled 81 patients with ascertained PC, 39 at initial staging and 42 in follow-up; the primary tumor had already been excised in 68 cases. Single Photon emission Computed Tomography (SPECT) images were reconstructed with the iterative method and fused with non-enhanced Computed tomography (CT) images. Results: Primary PC or metastatic lesions were ascertained in 55/81 patients and SPECT/CT was positive in 50/55 cases, while ceCT was positive in 44/55. Comparing SPECT/CT with ceCT results, we found a sensitivity of 96 vs. 87.5%, and specificity of 92% vs. 97% for the detection of primary lesion or recurrent disease. A total of 198 lesions were ascertained at SPECT/CT, while 161 at ceCT, with values of sensitivity and specificity of 85.5% and 84.6% for SRS and 75.2% and 90.5% respectively. Conclusion: 111In-Pentetreotide SPECT/CT proved to be more sensitive and accurate than ceCT, thus enhancing its role in evaluating patients with PC.

Original languageEnglish
Pages (from-to)4265-4270
Number of pages6
JournalAnticancer Research
Volume35
Issue number7
Publication statusPublished - Jul 1 2015

Fingerprint

Carcinoid Tumor
Tomography
Lung
Somatostatin Receptors
Radionuclide Imaging
Single-Photon Emission-Computed Tomography
Single Photon Emission Computed Tomography Computed Tomography
pentetreotide
Sensitivity and Specificity
Neoplasms

Keywords

  • <sup>111</sup>In-pentetreotide
  • NET
  • Pulmonary carcinoid
  • Scintigraphy
  • Somatostatin receptors
  • SPECT

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Chiaravalloti, A., Spanu, A., Danieli, R., Dore, F., Piras, B., Falchi, A., ... Schillaci, O. (2015). 111In-pentetreotide SPECT/CT in pulmonary carcinoid. Anticancer Research, 35(7), 4265-4270.

111In-pentetreotide SPECT/CT in pulmonary carcinoid. / Chiaravalloti, Agostino; Spanu, Angela; Danieli, Roberta; Dore, Francesca; Piras, Bastiana; Falchi, Antonio; Tavolozza, Mario; Madeddu, Giuseppe; Schillaci, Orazio.

In: Anticancer Research, Vol. 35, No. 7, 01.07.2015, p. 4265-4270.

Research output: Contribution to journalArticle

Chiaravalloti, A, Spanu, A, Danieli, R, Dore, F, Piras, B, Falchi, A, Tavolozza, M, Madeddu, G & Schillaci, O 2015, '111In-pentetreotide SPECT/CT in pulmonary carcinoid', Anticancer Research, vol. 35, no. 7, pp. 4265-4270.
Chiaravalloti A, Spanu A, Danieli R, Dore F, Piras B, Falchi A et al. 111In-pentetreotide SPECT/CT in pulmonary carcinoid. Anticancer Research. 2015 Jul 1;35(7):4265-4270.
Chiaravalloti, Agostino ; Spanu, Angela ; Danieli, Roberta ; Dore, Francesca ; Piras, Bastiana ; Falchi, Antonio ; Tavolozza, Mario ; Madeddu, Giuseppe ; Schillaci, Orazio. / 111In-pentetreotide SPECT/CT in pulmonary carcinoid. In: Anticancer Research. 2015 ; Vol. 35, No. 7. pp. 4265-4270.
@article{93dd48a209854c23a94b5c9cae6ef3e6,
title = "111In-pentetreotide SPECT/CT in pulmonary carcinoid",
abstract = "Aim: We evaluated somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). Patients and Methods: We enrolled 81 patients with ascertained PC, 39 at initial staging and 42 in follow-up; the primary tumor had already been excised in 68 cases. Single Photon emission Computed Tomography (SPECT) images were reconstructed with the iterative method and fused with non-enhanced Computed tomography (CT) images. Results: Primary PC or metastatic lesions were ascertained in 55/81 patients and SPECT/CT was positive in 50/55 cases, while ceCT was positive in 44/55. Comparing SPECT/CT with ceCT results, we found a sensitivity of 96 vs. 87.5{\%}, and specificity of 92{\%} vs. 97{\%} for the detection of primary lesion or recurrent disease. A total of 198 lesions were ascertained at SPECT/CT, while 161 at ceCT, with values of sensitivity and specificity of 85.5{\%} and 84.6{\%} for SRS and 75.2{\%} and 90.5{\%} respectively. Conclusion: 111In-Pentetreotide SPECT/CT proved to be more sensitive and accurate than ceCT, thus enhancing its role in evaluating patients with PC.",
keywords = "<sup>111</sup>In-pentetreotide, NET, Pulmonary carcinoid, Scintigraphy, Somatostatin receptors, SPECT",
author = "Agostino Chiaravalloti and Angela Spanu and Roberta Danieli and Francesca Dore and Bastiana Piras and Antonio Falchi and Mario Tavolozza and Giuseppe Madeddu and Orazio Schillaci",
year = "2015",
month = "7",
day = "1",
language = "English",
volume = "35",
pages = "4265--4270",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - 111In-pentetreotide SPECT/CT in pulmonary carcinoid

AU - Chiaravalloti, Agostino

AU - Spanu, Angela

AU - Danieli, Roberta

AU - Dore, Francesca

AU - Piras, Bastiana

AU - Falchi, Antonio

AU - Tavolozza, Mario

AU - Madeddu, Giuseppe

AU - Schillaci, Orazio

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Aim: We evaluated somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). Patients and Methods: We enrolled 81 patients with ascertained PC, 39 at initial staging and 42 in follow-up; the primary tumor had already been excised in 68 cases. Single Photon emission Computed Tomography (SPECT) images were reconstructed with the iterative method and fused with non-enhanced Computed tomography (CT) images. Results: Primary PC or metastatic lesions were ascertained in 55/81 patients and SPECT/CT was positive in 50/55 cases, while ceCT was positive in 44/55. Comparing SPECT/CT with ceCT results, we found a sensitivity of 96 vs. 87.5%, and specificity of 92% vs. 97% for the detection of primary lesion or recurrent disease. A total of 198 lesions were ascertained at SPECT/CT, while 161 at ceCT, with values of sensitivity and specificity of 85.5% and 84.6% for SRS and 75.2% and 90.5% respectively. Conclusion: 111In-Pentetreotide SPECT/CT proved to be more sensitive and accurate than ceCT, thus enhancing its role in evaluating patients with PC.

AB - Aim: We evaluated somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). Patients and Methods: We enrolled 81 patients with ascertained PC, 39 at initial staging and 42 in follow-up; the primary tumor had already been excised in 68 cases. Single Photon emission Computed Tomography (SPECT) images were reconstructed with the iterative method and fused with non-enhanced Computed tomography (CT) images. Results: Primary PC or metastatic lesions were ascertained in 55/81 patients and SPECT/CT was positive in 50/55 cases, while ceCT was positive in 44/55. Comparing SPECT/CT with ceCT results, we found a sensitivity of 96 vs. 87.5%, and specificity of 92% vs. 97% for the detection of primary lesion or recurrent disease. A total of 198 lesions were ascertained at SPECT/CT, while 161 at ceCT, with values of sensitivity and specificity of 85.5% and 84.6% for SRS and 75.2% and 90.5% respectively. Conclusion: 111In-Pentetreotide SPECT/CT proved to be more sensitive and accurate than ceCT, thus enhancing its role in evaluating patients with PC.

KW - <sup>111</sup>In-pentetreotide

KW - NET

KW - Pulmonary carcinoid

KW - Scintigraphy

KW - Somatostatin receptors

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=84937153697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937153697&partnerID=8YFLogxK

M3 - Article

C2 - 26124388

AN - SCOPUS:84937153697

VL - 35

SP - 4265

EP - 4270

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -